1. Genmab closes $2.5 billion offering of secured and unsecured notes. 2. Proceeds will fund the acquisition of Merus N.V. and related expenses. 3. The company restricts incurring additional debt and asset dispositions post-offering. 4. Notes were sold to qualified buyers; not registered under U.S. laws. 5. Acquisition might improve Genmab’s market position, influencing stock performance.